Canadian Company Groupe RSL Produces Canada’s First Lab-Grown Diamond Gem
20.9.2022 14:30:00 EEST | Business Wire | Press release
Groupe RSL is the first company to produce a Canadian lab-grown diamond gem, at its production facility in Quebec. The company is currently producing large diamonds for the premium jewellery market. With sustainability at the heart of its approach, Groupe RSL believes that lab diamonds have the potential to significantly reduce the environmental impacts of diamond production.
“Laboratory diamonds have the potential to revolutionize the industry, while reducing the environmental and human costs associated with diamond production,” said Luke Sinclair, CFO of Groupe RSL. “Consumers are seeking greater transparency in the diamonds that they purchase, and we firmly believe that the industry need not be at odds with the environment or principles of social responsibility. We are excited to see how the lab-grown diamond industry evolves over the coming years.”
Groupe RSL produces its diamonds locally in Quebec using a chemical vapour deposition, or CVD, process, whereby hydrogen and methane gas are combined in a plasma under precise conditions to grow diamonds one atom at a time over a period of several weeks to a month. Powered entirely by hydroelectricity, Groupe RSL has developed its own unique process to become the first Canadian company to use this approach to make diamond gems.
“For most of human scientific history, we thought that it was impossible to make diamonds in anything but the hottest high-pressure conditions. That’s why early attempts at man-made diamond focused on replicating the intense pressure that creates diamonds beneath the ground,” adds Sinclair. “Recent research has brought to light a new idea, using hydrogen and methane gas in a controlled reaction.”
Mined diamonds vs. lab-created diamonds
Mined diamonds and lab created diamonds are identical—chemically, physically and optically, and cannot be distinguished from one another without highly specialized equipment. In fact, mined diamonds often contain defects or impurities, both of which can be controlled or removed in lab diamonds.
Consumer shift
There has been a significant increase in demand for lab-grown diamonds in recent years, with lab diamond’s share of diamond sales more than doubling between 2020 and 2022.1 Millennials and Generation Z are moving away from mined diamonds, with nearly 70% of millennials considering buying a lab grown alternative.2 Consumers also seek greater transparency to ensure diamonds are sourced responsibly and produced sustainably. For example, nine in ten Generation Z consumers believe companies have a responsibility to address environmental and social issues.
About Groupe RSL Inc.
Groupe RSL Inc. is an innovative producer of diamond and the only Canadian producer of lab diamonds for the jewellery market. The company produces diamonds using a unique CVD process and technology. Groupe RSL produces beautiful and sustainable Canadian diamonds at its Quebec-based facility which is powered by 100% hydroelectricity. While their diamonds last forever, the company is committed to ensuring their ecological and social footprint does not. For more information, visit www.groupersl.com.
__________________________
1 Diamond industry analyst Edahn Golan. https://www.gemsociety.org/news/2022/05/18/interest-lab-grown-diamonds-surging-shows-no-signs-of-stopping/#:~:text=In%202020%2C%20lab%20diamond's%20share,be%20expected%2C%E2%80%9D%20said%20Golan
2 Millennial Consumer Research Lab Grown Diamonds, MVI Marketing LLC, May 3, 2018.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005008/en/
Contact information
Eric Aach
514-569-3594
eaach@national.ca
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 02:00:00 EEST | Press release
Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry,
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release
The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
